Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

Anxarecu. Annexin 2 validation as a recurrence predictor in endometrial cancer. Design of new therapeutic strategies.

The aim of the project is the development of a method for endometrial cancer recurrence prediction, based on Annexin 2 (ANXA2) expression, which allows both detection of patients likely to relapse at the time of diagnosis and clinical monitoring and validation of therapies directed to these patient populations.

Consortium with Formune Vaccines SL, Institut de Recerca Biomédica de Lleida, Fundació Privada Dr. Pifarré, Fundació Hospital Universitai Vall d'Hebrón - Institut de Recerca, Fundació Hospital Universitari Vall d'HEbron - Institut de Recerca.

Cofunded by the Ministerio de Economía y competitividad, within the call Retos-Colaboración del Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, in the frame of the Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016.

ID: RTC-2014-3110-1

2014-2016